Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) reported Q3 EPS of ($0.04), $0.05 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $3.5 million versus the consensus estimate of $1.9 million.

For earnings history and earnings-related data on Acadia Pharmaceuticals, Inc. (ACAD) click here.

Earnings